Biomarker and method for detecting HBV related hepatocellular carcinoma

Abstract

The invention relates to the field of medical science, and provides a biomarker for hepatocellular carcinoma related detection, particularly a biomarker for detecting HBV related hepatocellular carcinoma. The biomarker comprises an insulin-like growth factor binding protein 7 (IGFBP7) and an alpha fetoprotein (AFP). A method for detecting hepatocellular carcinoma, based on the biomarker namely the IGFBP7 and the AFP, comprises a step of carrying out judgement by measuring a marker IGFBP7 gene promotor methylation level and detecting the sensitivity of the marker AFP for being combined with serum IGFBP7 gene promoter methylation. According to biomarker, the AFP is combined with the IGFBP7 gene promoter methylation, so that the traditional detection of single indexes is changed, and the efficiency of HCC diagnosis is increased.

Description

technical field [0001] The invention relates to the medical field, and relates to a biomarker for detection related to hepatocellular carcinoma, in particular to a biomarker and method for detecting HBV-related hepatocellular carcinoma. Background technique [0002] HCC is the sixth most common tumor worldwide (749,000 new cases per year), and the third most deadly tumor (692,000 deaths per year). In addition, the incidence of HCC is increasing year by year in many countries. In recent years, although there have been many improvements in the treatment of HCC, the prognosis and 5-year survival rate of HCC patients are still not very optimistic (about 0-10%). The main reason for this situation is the lack of effective means for early diagnosis and monitoring. Once diagnosed, many patients are already in the terminal stage of the disease and lose the chance of treatment. Currently, the most commonly used HCC screening methods are serum AFP and ultrasound. However, they all ...

AI Technical Summary

Problems solved by technology

Liver puncture is an effective method for the diagno

Images